

EXECUTIVE SUMMARY

ACTION ITEM: Arizona State University requests authorization to approve a cooperative agreement from the National Institutes of Health (NIH), National Institute of Allergy & Infectious Disease (NIAID) #U01 AI061253.

ISSUE: The Board is requested to approve acceptance of a cooperative agreement to Arizona State University from the NIH-NIAID.

BACKGROUND:

- ASU has received a cooperative agreement from the NIH-NIAID for support of the Center for Infectious Diseases and Vaccinology (IDV), Biodesign Institute, Office of the Vice President for Research and Economic Affairs project. The obligated amount of the award is \$1,341,468.00 and the anticipated amount is \$3,930,794.00 federal funding. No matching or cost share is required.
- The objective of this project is to test the hypothesis that transgenic plants can be used to express Ebola virus specific recombinant immune complexes and that these will induce protective immunity in murine and non-human primates.
- ASU project director is Charles Arntzen, Center for Infectious Diseases and Vaccinology.
- The project period is March 15, 2005 through February 28, 2009.

RECOMMENDATION/CONCLUSION:

The Board of Regents authorizes ASU to finalize this agreement for this project for the Center for Infectious Diseases and Vaccinology.

Contact

Dr. Jonathan Fink 480/965-1224
Vice President for Research and Economic Affairs
jonathan.fink@asu.edu